Latest Breaking News On - Daniel hassett - Page 3 : comparemela.com

Effectiveness of ointment that kills drug-resistant bacteria shown

Research from the University of Cincinnati College of Medicine shows that use of a topical drug, called AB569, a combination of acidified nitrite and

Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006

Share this article NEW YORK, March 17, 2021 /PRNewswire/  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute ( UCRI ) to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan. HT-006 is a novel antibiotic under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia (HAP), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia (VAP).  Hoth previously licensed the HT-006 technology for commercial evaluation from the Walter Reed Army Institute of Research. We are pleased to commence a new research program with Dr. Hassett and the University of Cincinnati Research Institute, said Robb Knie, CEO of Hoth Therapeutics. There is a growing need for new antibiotic therapies targete

Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006